Effect of Chronic Dolutegravir Administration on the Trace Amine Profile in Wistar Rats
Abstract Background Dolutegravir (DTG), an integrase strand inhibitor, is currently used as the first-line treatment for HIV. Despite relatively poor tissue penetration, the risk of adverse effects in metabolic and excretory systems should be considered. The trace aminergic system and trace amines a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-08-01
|
| Series: | Drugs in R&D |
| Online Access: | https://doi.org/10.1007/s40268-024-00484-4 |